title: A role for oligonucleotide-based RNA-knock down technologies in functional genomics.
abstract: Functional genomics is inundating the pharmaceutical industry with large numbers of potential gene targets from several sources such as gene expression profiling experiments (DNA microchips, proteomics) or database mining. Oligonucleotide-based RNA-knock down technologies such as antisense or RNA interference can aid in the filtering and prioritization of target candidates in the drug discovery process.
authors.affiliation: Functional Genomics, Novartis Pharma AG, Basel, Switzerland.
authors.forename: Gabriele
authors.initials: G
authors.lastname: Dorn
authors.forename: Jonathan
authors.initials: J
authors.lastname: Hall
authors.forename: Dieter
authors.initials: D
authors.lastname: Hüsken
authors.forename: Jörg
authors.initials: J
authors.lastname: Lange
authors.forename: Pierre
authors.initials: P
authors.lastname: Martin
authors.forename: Francois
authors.initials: F
authors.lastname: Natt
authors.forename: William L
authors.initials: WL
authors.lastname: Wishart
authors.forename: Jan
authors.initials: J
authors.lastname: Weiler
mesh_terms: D004345:Drug Industry / Q000379:methods; D023281:Genomics; D020411:Oligonucleotide Array Sequence Analysis; D009843:Oligoribonucleotides / Q000138:chemical synthesis*; D012313:RNA / Q000235:genetics; D034741:RNA, Small Interfering / Q000737:chemistry / Q000235:genetics
chemical_list: D009843:Oligoribonucleotides; D034741:RNA, Small Interfering; D012313:RNA